Efficacy and safety of reinfusion of concentrated ascitic fluid for malignant ascites: a concept-proof study

Purpose Malignant ascites is one of the symptoms causing discomfort in advanced cancer patients. Cell-free and concentrated ascites reinfusion therapy (CART) is one treatment modality, but controlled trials are limited. The primary aim of this study was to explore the efficacy and safety of CART, as...

Full description

Saved in:
Bibliographic Details
Published in:Supportive care in cancer 2018-05, Vol.26 (5), p.1489-1497
Main Authors: Hanada, Rumi, Yokomichi, Naosuke, Kato, Chihiro, Miki, Kazumi, Oyama, Sachiko, Morita, Tatsuya, Kawahara, Ryoko
Format: Article
Language:English
Subjects:
Albumin
Analysis
Ascites
Body fluids
Cancer
Cancer patients
Cancer therapies
Care and treatment
Complications and side effects
Medical research
Medicine
Medicine & Public Health
Nursing
Nursing Research
Oncology
Original Article
Pain
Pain Medicine
Palliative care
Rehabilitation Medicine
White blood cell count
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Malignant ascites is one of the symptoms causing discomfort in advanced cancer patients. Cell-free and concentrated ascites reinfusion therapy (CART) is one treatment modality, but controlled trials are limited. The primary aim of this study was to explore the efficacy and safety of CART, as well as their predictors, to obtain data for planning a further controlled trial. Methods This was a single center retrospective cohort study in patients with refractory malignant ascites. Consecutive adult patients who underwent CART were enrolled. The primary endpoints were the time to next paracentesis and seven patient-reported symptoms (e.g., abdominal pain and distension). The secondary endpoints were adverse events, laboratory findings, and physical findings. Results A total of 104 CART procedures for 51 patients were analyzed. The median time to next paracentesis was 27 days (95% CI, 21–35). Intensities of all seven symptoms were significantly improved after CART ( p  
ISSN:0941-4355
1433-7339
DOI:10.1007/s00520-017-3980-5